- Profile
- Personal Information
- Publications
Experts in Business and Management
Gerhard J. Barone Dr. Hanumant Yadav Jack Jonck DOÄžANAY, Mehmet Mete Bernardo Balboni G. Eddy Birrer Cem Behar Bin Ke Cengiz Kallek Michael Frese Engin Akarli Andrew M. Brajcich Robert Lee Ensar Gul Irene Elisabeth De Pater RUOLIAN FANG REMUS ILIES Geraldo Cerqueiro Timothy G. Coville Ghee Soon Lim View MoreHans Schikan currently serves as Chair of the Board of Directors for InteRNA (Netherlands), Complix (Belgium) and Asceneuron (Switzerland) in addition to serving on the boards of Swedish public companies Swedish Orphan Biovitrum, Wilson Therapeutics and Hansa Medical. Furthermore, he is member of the Top Team of the Dutch Top Sector Life Sciences & Health (Netherlands). Previously, Hans Schikan was the CEO of Prosensa, which used RNA modulating treatments to treat rare diseases such as Duchenne muscular dystrophy. During his time at Prosensa, he oversaw the listing of the company on Nasdaq and the conclusion of an M&A deal with BioMarin for up to $840 million. Prior to that, Hans Schikan held senior positions in Global Marketing and Strategic Development at Genzyme and leadership roles at Organon. Hans Schikan received his Pharm.D. from the University of Utrecht (Netherlands).
Global Marketing and Strategic Development